ABIOMED, Inc.

It's now my pleasure to turn the conference over to Vice President of Investor Relations, Jessica Moore. Please go ahead.

Thank you, Daryl, and welcome, everyone. This is Jessica Moore, Vice President of Investor Relations for Johnson & Johnson. We appreciate everyone joining us on such short notice to review today's exciting announcement that Johnson & Johnson has entered into a definitive agreement to acquire Aviomed. Please note you can find today's presentation on the Investor Relations section of the Johnson & Johnson website at investor.jnj.com following the call. With us this morning are Joaquin DeWato, Chief Executive Officer of Johnson & Johnson, Michael R. Minogue, Abiy Ahmed's Chairman, President, and Chief Executive Officer, Ashley McAvoy, Executive Vice President and Worldwide Chairman of MedTech at Johnson & Johnson, and Joe Wach, Chief Financial Officer of Johnson & Johnson. Here is a quick outline of what we're going to cover on today's call. Joaquin will start by providing a high-level overview of the strategic rationale and how Abiomed helps the company accelerate our vision for the new Johnson & Johnson. Mike will then provide a brief overview of Abiomed. Then Ashley will go into more detail on how Abiomed's clinical profile fits into our MedTech strategy and the incredible opportunities we see for the business moving forward. Finally, Joe will cover the financial details and Abiomed's significant revenue growth potential. We will then open the call to questions. We expect the call to last up to 60 minutes. Please note that today's presentation and statements from both companies are or may be considered forward-looking statements. Please refer to each company's website for their publicly available filings that identify certain factors which could cause actual results to differ materially from those projected in any forward-looking statements made today. Investors are therefore cautioned not to rely on these forward-looking statements. The companies do not undertake to update any forward-looking statements as a result of new information or future events. I'll now turn the call over to Joaquin.

Thanks, Jessica, and good morning, everyone. Thank you all for tuning in. As you saw, this morning we announced an important step in the execution of our strategic priorities and our vision for the new Johnson & Johnson focused on pharmaceutical and medtech. we have entered into a definitive agreement for Johnson & Johnson to acquire a biomed. One of the three strategic priorities that I have consistently communicated since assuming the role of Johnson & Johnson's CEO earlier this year is driving our medtech business to best-in-class performance. Achievement of this priority includes strengthening our positions in high-growth medtech markets through investments in both organic innovation programs and value-creating inorganic opportunities. The addition of Abiomed provides a strategic platform to advance breakthrough treatments in cardiovascular disease and help more patients around the world while driving value for our shareholders. Taking a step back, we are at an important moment in healthcare. Good health is the foundation for a better future, yet healthcare continues to be the biggest challenge facing society today. Our purpose at Johnson & Johnson is to blend heart, science, and ingenuity to profoundly change the future of health for humanity. We are proud of the role our company plays in offering life-saving treatments and medical device solutions to address the most challenging diseases worldwide. You may have heard me say that I believe that we can advance healthcare more over the next decade than we have in the last century. Focusing on scientific R&D and patient and disease-centric care is critical to achieve these advancements. This transaction underscores our focus on not only continuing to improve and grow our medtech business, but also delivering industry-leading innovation and technology with the goal of bringing new solutions to market for patients and healthcare systems worldwide. As many of you know, a biomed is a world leader in breakthrough heart, lung, and kidney support technologies with a first in kind portfolio for the treatment of coronary artery disease and heart failure. A biomed operates in one of the fastest growing med tech segments with significant expansion opportunities in indication, geography, and product. Cardiovascular disease is the number one cause of death. All forms of cardiovascular disease lead to heart failure, which is a significant cost to health systems due to hospitalizations and extended length of stay. As the leading innovator in heart failure, a biomed already has a compelling clinical evidence demonstrated by the FDA granting several pre-market approval indications for the Impella Heart Pump portfolio. These approvals recognize both safety and effectiveness for patients with severe coronary artery disease requiring high-risk percutaneous coronary intervention, treatment of acute myocardial infraction, cardiogenic shock, or right heart failure. In addition, a biomed has a robust platform and an extensive pipeline of life-saving technologies and ongoing clinical studies with significant potential for long-term innovation and indication expansion. Johnson & Johnson's global footprint, leading capabilities in physician education, commercial excellence, and robust clinical expertise will complement AvioMed's capabilities, accelerating access and adoption of life-saving technologies for more patients around the world. All while moving Johnson & Johnson into higher growth markets, accelerating near and long-term sales and earnings growth. Before I pass it over to Mike Minosh, CEO at Abiomed, I have to acknowledge that this is a unique moment, deeply rooted in the commitment to our credo that has set Johnson & Johnson apart for well over a century. Our remarkable success for more than 135 years has been achieved by prioritizing the needs and well-being of the people we serve and staying true to our mission to deliver for patients, doctors, nurses, mothers and fathers, and all others who use our products and services. By bringing Abiomed into Johnson & Johnson, our complementary cultures, patient-first mindsets, strength of Abiomed's current and future portfolio, and Johnson & Johnson capabilities and global scale, we will drive heart recovery to be the global standard of care. Finally, I want to say how much I have truly enjoyed getting to know Mike and the Abiomed team. Ashley knew Mike from AdvaMed and we have admired the Adviomed business for a while. We are confident in the cultural fit between our companies. Now, I will turn it over to Mike Minosh.